References
- NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990–May 1999, issued June 1999. Am J Infect Control 1999;27:520–32
- Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47–54
- Centers for Disease Control. Staphylococcus aureus resistant to vancomycin – United States, 2002. Morb Mortal Wkly Rep 2002;51:565–7
- Lew DP, Waldvogel SA. Osteomyelitis. N Engl J Med 1997;336:999–1007
- Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227–31
- Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261–8
- Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004;32:8–14
- Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop 2004;67–71
- Liao CH, Tseng SP, Fang CT, et al. First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother 2005;55:598–9
- Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005;330:102–4
- Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517–20
- MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51\(Suppl 2):ii17–25
- Arbeit RD, Maki D, Tally FP, et al., Daptomycin 98–01 and 99–01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2004;38:1673–81
- Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000;46:523–6
- Thorne GM. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newsl 2002;24:33–40
- Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674–80
- Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799–802